Peptilex
Study tracker · Weight · Diabetes

Tirzepatide

Updated 19 Oct 2026 · Peptilex evidence grade A (A = approved, large trials · D = mainly animal studies)

Approved (Mounjaro, Zepbound). In SURMOUNT-5 it beat semaglutide head-to-head (20.2% vs 13.7% weight loss over 72 weeks); new trials cover heart outcomes in obesity, sleep apnea, type 1 diabetes and more.
2,637PubMed papers
1,434Human studies
134Randomized trials
189Registered studies
115Ongoing / starting
79Phase 3+

Registered trials

From ClinicalTrials.gov, matched by name in the study title.

StudyPhaseStatusParticipantsStart
A Study of Tirzepatide (LY3298176) Compared With Standard of Care in Adult Participants With Obesity and Without Diabetes (SURMOUNT-REAL UK)
NCT07247084 · Eli Lilly and Company
Phase 4Recruiting3,0002025-11
A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes
NCT05433584 · Eli Lilly and Company
Phase 4Running7802022-08
Subcutaneous Tirzepatide Once-weekly in Patients With Obesity and Knee Osteoarthritis (STOP KNEE-OA)
NCT06191848 · University of Melbourne
Phase 4Running3522024-11
A Study of Tirzepatide (LY3298176) in Adult Participants in India With Either Type 2 Diabetes Mellitus or Obesity
NCT07438444 · Eli Lilly and Company
Phase 4Running3442026-02
A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
NCT06857942 · Eli Lilly and Company
Phase 4Recruiting2002025-03
A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)
NCT06864026 · Eli Lilly and Company
Phase 4Running2002025-03
A Clincial Study Testing Tirzepatide on Reproductive Function and Metabolic Health in Women With PCOS Who Are Overweight or Obese
NCT07326111 · University of Bonn
Phase 4Recruiting1982025-12
Efficacy, Safety, and Tolerability of Tirzepatide in Real-World Conditions in Paraguay.
NCT07588438 · Las Rías Medical Center
Phase 4Recruiting1602026-07
Resistance Training to Prevent Muscle Loss During Treatment With Tirzepatide
NCT07777575 · Technical University of Munich
Phase 4Recruiting1502026-09
Effects of Tirzepatide and Insulin Glargine on Glucolipid Metabolism and Brain Function in Patients With Type 2 Diabetes
NCT05553093 · Nanjing First Hospital, Nanjing Medical University
Phase 4Recruiting1502022-03
Bariatric Surgery vs. Semaglutide vs. Tirzepatide
NCT06803888 · Ali Aminian
Phase 4Running1402025-01
The Effects of Tirzepatide in People With Overweight/Obesity and Coronary Artery Disease
NCT06606821 · Tina Vilsbøll
Phase 4Recruiting1242024-10
Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT
NCT05708859 · Matthew J. Budoff
Phase 4Recruiting1202024-01
Normal-weight Diabetes: Adipocyte-directed Therapy With Pioglitazone or Tirzepatide
NCT06657209 · Stanford University
Phase 4Recruiting1042025-01
Tirzepatide in Idiopathic Intracranial Hypertension Trial
NCT07191873 · Duke University
Phase 4Recruiting602026-08
Tirzepatide Use in People With Obesity and Type 1 Diabetes
NCT07096908 · Dasman Diabetes Institute
Phase 4Recruiting602025-07
Tirzepatide's Effects on Epigenetic Aging and Metabolic Restoration in Virally Suppressed People With HIV
NCT07707778 · National Taiwan University Clinical Trial Center
Phase 4Enrolling602026-06
2024 Tirzepatide-Bariatric Surgery
NCT06721507 · Marlene Starr
Phase 4Recruiting502025-03
The Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women With Obesity
NCT07218445 · Mayo Clinic
Phase 4Recruiting402026-04
Tirzepatide in PWS, HO and GNSO
NCT06901245 · Grace Kim
Phase 4Recruiting362025-05
Tirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors
NCT07257484 · Weill Medical College of Cornell University
Phase 4Recruiting302026-06
Tirzepatide (Spartina) in Obese Kidney Transplant Recipients
NCT07423247 · Shahid Beheshti University of Medical Sciences
Phase 4Recruiting302026-01
A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity
NCT05556512 · Eli Lilly and Company
Phase 3Running15,3742022-10
A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight
NCT06914895 · Eli Lilly and Company
Phase 3Running9052025-04
A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity
NCT06662383 · Eli Lilly and Company
Phase 3Running8002024-11

1 further registry entry from a sponsor we could not verify is not listed.

Showing 25 of 189 matching registered studies (ongoing first). See all on ClinicalTrials.gov.

Latest randomized trials & key papers

From PubMed. The full story – mechanism, all results, risks – is in the Tirzepatide profile of the book.

Peptilex – The Honest GLP-1 Handbook, book cover

New: The Honest GLP-1 Handbook

Semaglutide, tirzepatide and the new pills, explained for adults over 50: what the trials show, a symptom-by-symptom side-effect troubleshooter, muscle and protein, and what happens when you stop. 172 pages.

Coming soon
Peptilex – The Peptide Encyclopedia, book cover

34 peptides. One book.

A science-based guide for beginners to 34 peptides: what each one does, the most exciting research results, and where it stands in 2026. Every profile: what it is, the most exciting results, key studies, risks and open questions.

KindlePaperbackHardcover